Literature DB >> 8940749

Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control.

Y Nishimura1, Y Nagata, K Okajima, M Mitsumori, M Hiraoka, S Masunaga, K Ono, K Shoji, H Kojima.   

Abstract

PURPOSE: Local control probabilities of T1,2 glottic laryngeal cancer were evaluated in relation to dose and fractionation of radiation therapy (RT).
MATERIALS AND METHODS: Between 1975 and 1993, 96 T1N0M0 glottic cancers and 32 T2N0M0 glottic cancers were treated with definitive RT. Total RT dose was 60-66 Gy/2 Gy for most of the T1 and T2 tumors, although 10 T2 tumors were treated with hyperfractionation (72-74.4 Gy/1.2 Gy bid). Of the 128 patients, 90 T1 glottic tumors and 30 T2 glottic tumors were followed for > 2 years after treatment. Multivariate analyses using the Cox proportional hazards model and a logistic regression analysis were performed to evaluate the significance of prognostic variables on local control.
RESULTS: The 5-year local control probability for T1 tumors was 85%, whereas that for T2 tumors was 71%. Multivariate analyses demonstrated that only overall treatment time (OTT) was a significant variable for local control. Total RT dose, normalized total doses at a fraction size of 2 Gy, and fraction size were not significant. Local control probability of T1 tumors with an OTT of 42-49 days was significantly higher than that of tumors with an OTT of > 49 days (P < 0.02). Only a 1-week interruption of RT, due to holidays, significantly reduced the 5-year local control probability of T1 glottic tumors from 89 to 74% (P < 0.05).
CONCLUSIONS: These results indicate that OTT is a significant prognostic factor for local control of T1 glottic tumors.

Entities:  

Mesh:

Year:  1996        PMID: 8940749     DOI: 10.1016/0167-8140(96)01796-3

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  14 in total

1.  Hyperfractionated radiotherapy for T2 glottic cancer for preservation of the larynx.

Authors:  Ichiro Tateya; Shigeru Hirano; Hisayoshi Kojima; Koichi Omori; Kazuhiko Shoji; Michihide Mitsumori; Yasushi Nagata; Juichi Ito
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-07-13       Impact factor: 2.503

2.  Outcome of radiotherapy in T1 glottic carcinoma: a population-based study.

Authors:  Elisabeth Victoria Sjögren; Ruud G J Wiggenraad; Saskia Le Cessie; Simone Snijder; Jaqueline Pomp; Robert Jan Baatenburg de Jong
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-10-07       Impact factor: 2.503

3.  [Non- inferior moderate hypofractionated irradiation of glottis T1/T2 laryngeal cancer ].

Authors:  Martina Becker-Schiebe; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2014-07       Impact factor: 3.621

4.  Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer.

Authors:  Matthew P Deek; Sinae Kim; Inaya Ahmed; Bruno S Fang; Wei Zou; Jyoti Malhotra; Joseph Aisner; Salma K Jabbour
Journal:  Am J Clin Oncol       Date:  2018-04       Impact factor: 2.339

Review 5.  3D conformal hypofractionated radical radiotherapy in early glottic cancer.

Authors:  Ana Cristina Amado; Laurentiu Bujor; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-05-30

Review 6.  Therapeutic modalities and oncologic outcomes in the treatment of T1b glottic squamous cell carcinoma: a systematic review.

Authors:  Federico Maria Gioacchini; Michele Tulli; Shaniko Kaleci; Stefano Bondi; Mario Bussi; Massimo Re
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-09-19       Impact factor: 2.503

7.  Multidisciplinary approach in the treatment of T1 glottic cancer. The role of patient preference in a homogenous patient population.

Authors:  Nicola Dinapoli; Claudio Parrilla; Jacopo Galli; Rosa Autorino; Francesco Miccichè; Francesco Bussu; Mario Balducci; Lucia D'Alatri; Raffaella Marchese; Mario Rigante; Giuseppe Di Lella; Luca Liberati; Giovanni Almadori; Gaetano Paludetti; Vincenzo Valentini
Journal:  Strahlenther Onkol       Date:  2010-11-08       Impact factor: 3.621

8.  Predictive factors for local control of early glottic squamous cell carcinomas after definitive radiotherapy.

Authors:  Mitsuru Okubo; Tomohiro Itonaga; Tatsuhiko Saito; Sachika Shiraishi; Ryuji Mikami; Akira Sakurada; Shinji Sugahara; Jinho Park; Koichi Tokuuye; Kazuhiro Saito
Journal:  Mol Clin Oncol       Date:  2020-03-30

9.  Radiotherapy concurrently with weekly cisplatin, followed by adjuvant chemotherapy, for N2-3 nasopharyngeal cancer: a multicenter trial of the Forum for Nuclear Cooperation in Asia.

Authors:  Tatsuya Ohno; Dang Huy Quoc Thinh; Shingo Kato; C R Beena Devi; Ngo Thanh Tung; Kullathorn Thephamongkhol; Miriam Joy C Calaguas; Juying Zhou; Yaowalak Chansilpa; Nana Supriana; Dyah Erawati; Parvin Akhter Banu; Cho Chul Koo; Kunihiko Kobayashi; Takashi Nakano; Hirohiko Tsujii
Journal:  J Radiat Res       Date:  2012-11-28       Impact factor: 2.724

10.  Concurrent hyperfractionated chemoradiotherapy for head and neck squamous cell carcinoma: the prognostic impact of the overall treatment time and completion rates of chemotherapy.

Authors:  Masami Fujii; Takayuki Ohguri; Katsuya Yahara; Hajime Imada; Kyosuke Tomura; Mai Sakagami; Gunji Nagatani; Hideaki Suzuki; Yukunori Korogi
Journal:  Springerplus       Date:  2015-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.